Alector Inc., a late-stage clinical biotechnology company, released its first-quarter 2025 financial results, reporting $3.7 million in collaboration revenue, a significant decrease from the $15.9 million reported in the same period of 2024. This decline was primarily attributed to the satisfaction of performance obligations related to the AL002 program and the latozinemab FTD-_C9orf72_ Phase 2 trial in the fourth quarter of 2024. The company reported a net loss of $40.5 million for the quarter ended March 31, 2025, compared to a net loss of $36.1 million during the same period in 2024. Research and development expenses decreased to $33.6 million from $45.2 million in the previous year, mainly due to reductions in the AL002 program and personnel costs. General and administrative expenses slightly increased to $14.7 million from $14.4 million in the first quarter of 2024. In terms of business updates, Alector is on track to report topline data from its INFRONT-3 Phase 3 clinical trial of latozinemab in frontotemporal dementia with a granulin gene mutation by the fourth quarter of 2025. The company also completed enrollment in the PROGRESS-AD Phase 2 trial of AL101 in early Alzheimer's disease. Alector's cash position, totaling $354.6 million, is anticipated to support operations into the second half of 2027, allowing the company to continue advancing its portfolio of drug candidates for neurodegenerative diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.